Last reviewed · How we verify
Daytrana
At a glance
| Generic name | Daytrana |
|---|---|
| Also known as | MTS, methylphenidate transdermal system |
| Sponsor | Noven Therapeutics |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Boxed warnings
- WARNING: ABUSE, MISUSE, AND ADDICTION DAYTRANA has a high potential for abuse and misuse, which can lead to the development of substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including DAYTRANA, can result in overdose and death [see Overdosage ( 10 )] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing DAYTRANA, assess each patient’s risk for abuse, misuse, and addiction. Educat
Common side effects
- Appetite decreased
- Insomnia
- Nausea
- Weight decreased
- Vomiting
- Anorexia
- Tic
- Affect lability
- Dizziness
- Abdominal pain
- Application site reactions
- Headache
Key clinical trials
- Orexin s Role in the Neurobiology of Substance Use Disorder (NA)
- The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (PHASE4)
- Benefits of ADHD Treatment in Detained People (PHASE3)
- Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease (PHASE1)
- A Trial to Assess How Centanafadine Interacts With Stimulants in the Body (PHASE1)
- Comorbidity Between Attention Deficit Hyperactivity Disorder and Fibromyalgia (NA)
- The Effect Of Methylphenıdate Treatment On Neuroınflammatıon Levels In Chıldren Wıth Attentıon Defıcıt Hyperactıvıty Dısorder
- Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Daytrana CI brief — competitive landscape report
- Daytrana updates RSS · CI watch RSS
- Noven Therapeutics portfolio CI